Your browser doesn't support javascript.
loading
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
Hibma, Jennifer E; O'Gorman, Melissa; Nepal, Sunil; Pawlak, Sylvester; Ginman, Katherine; Pithavala, Yazdi K.
Afiliación
  • Hibma JE; Pfizer (Clinical Pharmacology Oncology), La Jolla, 10555 Science Center Drive, CB10-2727, San Diego, CA, 92121, USA. Jennifer.e.hibma@pfizer.com.
  • O'Gorman M; Pfizer (Pharmacometrics Oncology), Groton, CT, USA.
  • Nepal S; Pfizer (Statistics Oncology), Groton, CT, USA.
  • Pawlak S; Independent Statistical Consultant, Schwenksville, PA, USA.
  • Ginman K; Pfizer (Clinical Development and Operations), New Haven, CT, USA.
  • Pithavala YK; Pfizer (Clinical Development and Operations), South Lyon, MI, USA.
Cancer Chemother Pharmacol ; 89(1): 71-81, 2022 01.
Article en En | MEDLINE | ID: mdl-34698901
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Pirazoles / Quinasa de Linfoma Anaplásico / Aminopiridinas / Lactamas Tipo de estudio: Clinical_trials Idioma: En Revista: Cancer Chemother Pharmacol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Pirazoles / Quinasa de Linfoma Anaplásico / Aminopiridinas / Lactamas Tipo de estudio: Clinical_trials Idioma: En Revista: Cancer Chemother Pharmacol Año: 2022 Tipo del documento: Article